AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE | A077183 | DR REDDYS LABORATORIES INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Pfizer Inc FDA-2007-P-0350 · 6 docket documents Pfizer Inc submitted this citizen petition on March 21, 2007, requesting that the FDA rescind final approval of Novartis's NDA 20-364 for Lotrel (amlodipine besylate and benazepril hydrochloride) and withhold approval of any supplemental NDAs, arguing that the Lotrel NDA should be reclassified as a | 505(q) | 2008-05-23 | Denied | Pfizer Inc |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1171
per ea
Lowest NADAC/Unit
$0.1032
per ea
Brand NDCs
0
Generic NDCs
7
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 55111034105AMLODIPINE-BENAZEPRIL 10-20 MG | $0.1171 | EA | Generic | — | 2026-06-17 |
| 55111034101AMLODIPINE-BENAZEPRIL 10-20 MG | $0.1171 | EA | Generic | — | 2026-06-17 |
| 55111033801AMLODIPINE-BENAZEPRIL 2.5-10 | $0.1056 | EA | Generic | — | 2026-06-17 |
| 55111034001AMLODIPINE-BENAZEPRIL 5-20 MG | $0.1040 | EA | Generic | — | 2026-06-17 |
| 55111034005AMLODIPINE-BENAZEPRIL 5-20 MG | $0.1040 | EA | Generic | — | 2026-06-17 |
| 55111033905AMLODIPINE-BENAZEPRIL 5-10 MG | $0.1032 | EA | Generic | — | 2026-06-17 |
| 55111033901AMLODIPINE-BENAZEPRIL 5-10 MG | $0.1032 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.